Besides, Liu and Chen [41,42] discovered that NR4A1 could be a critical general regulator in the induction of T cell dysfunction and inhibit NR4A, thus, NR4A1 was seen as promising in cancer immunotherapy. The gene discussed is NR4A1; the disease is cancer.